InspireMD, Inc. (NSPR)
After hours:
| Previous close | 3.3800 |
| Open | 3.3500 |
| Bid | 3.0600 x 900 |
| Ask | 3.6100 x 1100 |
| Day's range | 3.2400 - 3.4000 |
| 52-week range | 0.8100 - 3.7700 |
| Volume | |
| Avg. volume | 86,056 |
| Market cap | 68.672M |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9500 |
| Earnings date | 06 Nov 2023 - 10 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.35 |
GlobeNewswireInspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
TEL AVIV, Israel, and MIAMI, Aug. 31, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. IDE clinical trial has been accepted for presentation as a late-breaking clinical trial at the Vascular InterVentional Advances Annual Meeting (VIVA23), which is being held October 30 through November 2 in Las Vegas. Pr
- GlobeNewswire
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and secondary endpoints and, if successful, submit PMA application in H2 2024 – - Generated Q2 2023 CGuard EPS revenue of $1.6 million, an increase of nearly 10% over Q2 2022 – --Management to host investor conference call today, August 8, at 8:30am ET-- TEL AVIV, Israel, and MIAMI, Aug. 08, 2023 (GLOBE NEW
- GlobeNewswire
InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2023 financial results on Tuesday, August 8thth, 2023, before the financial markets open. Management will host a conference call and webcast with the investment comm
